english.prescrire.org > Prescrire International > N°177 - December 2016

n°177

December 2016

Issue Contents
Editorial

Free  Long-term harms

p.284
Diethylstilbestrol and the very long-term effects of drugs

New Products


Trametinib (Mekinist°)

p.285-288
Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life

Nivolumab (Opdivo°)

p.289-292
BRAF V600 mutation-negative metastatic or inoperable melanoma: survival advantage

INN Common stem: -xaban

p.292

Free  Cobimetinib (Cotellic°) and metastatic melanoma

p.293
BRAF V600 mutation: a second MEK kinase inhibitor

Adverse Effects


Diethylstilbestrol (DES): also harms the third generation

p.294-298
Monitoring of children of DES daughters is needed

Transgenerational effects of DES: what mechanisms are implicated?

p.297

Mirtazapine and mianserin: QT prolongation and torsades de pointes

p.298
ECG monitoring is key

Reviews


Resectable non-small cell lung cancer

p.299-301
Adjuvant chemotherapy: slightly longer survival

Pneumococcal vaccination in persons at high risk

p.302-304
Use of the 23-valent unconjugated vaccine is questionable

Outlook


Prescrire's Médicaments en Questions: first results of a practice improvement programme

p.305-306
Taking harmful effects of drugs into account

Correction : Alzheimer's disease

p.306

Free  Patients want to be heard

p.307
Patients need solid data to participate in rational decision-making

Masthead


Free  Masthead

p.282

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe